Agora 10-Q 11 Aug 14 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Jun. 27, 2014	Jul. 29, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'ADVANCED PHOTONIX INC,	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--03-31	'
Entity Common Stock, Shares Outstanding	'	37,381,413
Amendment Flag	'false	'
Entity Central Index Key	'0000869986	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	27-Jun-14	'
Document Fiscal Year Focus	'2015	'
Document Fiscal Period Focus	'Q1	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Jun. 27, 2014	Mar. 31, 2014
Current assets:	'	'
Cash and cash equivalents	$1,433,000	$120,000
Receivables, net	5,013,000	5,085,000
Inventories	4,685,000	4,749,000
Prepaid expenses and other current assets	732,000	444,000
Total current assets	11,863,000	10,398,000
Equipment and leasehold improvements, net	1,930,000	2,144,000
Goodwill	4,579,000	4,579,000
Intangibles and patents, net	2,772,000	2,942,000
Other assets	190,000	138,000
Total Assets	21,334,000	20,201,000
Current liabilities:	'	'
Accounts payable	1,926,000	2,661,000
Accrued compensation	916,000	701,000
Accrued subcontracting costs	322,000	344,000
Other accrued expenses	1,217,000	1,108,000
Current portion of long-term debt, PFG	714,000	714,000
Current portion of long-term debt – MEDC/MSF	654,000	654,000
Current portion of capital lease	16,000	20,000
Current portion of long-term debt - bank line of credit	1,294,000	2,147,000
Current portion of long-term debt - bank term loan	250,000	306,000
Total current liabilities	7,309,000	8,655,000
Long-term debt, less current portion – PFG, net of discount	653,000	794,000
Long-term debt, capital lease	34,000	36,000
Warrant liability	364,000	409,000
Total liabilities	8,360,000	9,894,000
Commitments and contingencies	'	'
Class A Common Stock, $.001 par value, 100,000,000 authorized; 37,381,413 shares issued and outstanding as of June 27, 2014, and 31,203,213 shares issued and outstanding as of March 31, 2014	37,000	31,000
Additional paid-in capital	61,681,000	58,752,000
Accumulated deficit	-48,744,000	-48,476,000
Total shareholders' equity	12,974,000	10,307,000
Total Liabilities and Shareholders’ Equity	$21,334,000	$20,201,000

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Jun. 27, 2014	Mar. 31, 2014
Class A Common Stock, par value (in Dollars per share)	$0.00	$0.00
Class A Common Stock, authorized	100,000,000	100,000,000
Class A Common Stock, shares issued	37,381,413	31,203,213
Class A Common Stock, shares outstanding	37,381,413	31,203,213

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Jun. 27, 2014	Jun. 28, 2013
Sales, net	$7,663,000	$7,078,000
Cost of products sold	4,744,000	4,151,000
Gross profit	2,919,000	2,927,000
Operating expenses:	'	'
Research, development and engineering	1,009,000	1,492,000
Sales and marketing	570,000	587,000
General and administrative	1,276,000	1,124,000
Amortization expense	205,000	250,000
Total operating expenses	3,060,000	3,453,000
Loss from operations	-141,000	-526,000
Other income (expense):	'	'
Interest expense	-181,000	-160,000
Change in fair value of warrant liability	45,000	-196,000
Other income or (expense), net	9,000	-43,000
Total other expense	-127,000	-399,000
Loss before benefit for income taxes	-268,000	-925,000
Benefit for income taxes	0	0
Net loss	($268,000)	($925,000)
Basic and diluted loss per share (in Dollars per share)	($0.01)	($0.03)
Weighted average common shares outstanding	'	'
Basic and diluted (in Shares)	32,642,000	31,198,000

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Jun. 27, 2014	Jun. 28, 2013
Cash flows from operating activities:	'	'
Net loss	($268,000)	($925,000)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	174,000	222,000
Amortization of intangible assets	205,000	250,000
Amortization of debt discount	39,000	47,000
Stock based compensation expense	21,000	29,000
Change in fair value of warrant liability	-45,000	196,000
Non cash foreign currency translation loss	'	32,000
Changes in operating assets and liabilities:	'	'
Accounts receivable – net	72,000	'
Inventories	64,000	-450,000
Prepaid expenses and other assets	-340,000	48,000
Accounts payable and accrued expenses	-433,000	88,000
Net cash used in operating activities	-511,000	-463,000
Cash flows from investing activities:	'	'
Capital expenditures	-85,000	-31,000
Proceeds from sale of property and equipment	125,000	'
Patent expenditures	-35,000	-64,000
Net cash provided by or (used in) investing activities	5,000	-95,000
Cash flows from financing activities:	'	'
Net proceeds or (payments) on bank line of credit	-853,000	922,000
Payments on bank term loan	-56,000	-84,000
Payments on MEDC/MSF term loans	'	-136,000
Payments on PFG term loan	-180,000	-178,000
Payments on capital leases	-6,000	'
Net proceeds for issuance of Class A Common Stock	2,914,000	'
Net cash provided by financing activities	1,819,000	524,000
Effect of exchange rate changes on cash and cash equivalents	'	-4,000
Net increase or (decrease) in cash and cash equivalents	1,313,000	-38,000
Cash and cash equivalents at beginning of period	120,000	619,000
Cash and cash equivalents at end of period	1,433,000	581,000
Supplemental disclosure of cash flow information:	'	'
Cash paid for interest	97,000	92,000
Supplemental disclosure of non-cash investing and financing activities:	'	'
Acquisition of equipment through capital lease	'	$50,000

Note_1_Basis_of_Presentation

Note 1 - Basis of Presentation	3 Months Ended
	Jun. 27, 2014
Disclosure Text Block [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	Note 1.   Basis of Presentation
	Business Description
	General – Advanced Photonix, Inc. ® (the Company, we, us, our, or API), was incorporated under the laws of the State of Delaware in June 1988. API is a leading test and measurement company that packages optoelectronic semiconductors into high-speed optical receivers (HSOR products), custom optoelectronic subsystems (Optosolutions products) and Terahertz (THz products) instrumentation, serving the test and measurement, telecommunication, military/aerospace and medical markets. The Company supports the customers from the initial concept and design phase of the product, through testing to full-scale production. The Company has two manufacturing facilities located in Camarillo, California and Ann Arbor, Michigan.
	The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and the Company’s wholly owned subsidiaries (Silicon Sensors Inc., Picometrix®, LLC, and Advanced Photonix Canada, Inc.). The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). All material inter-company accounts and transactions have been eliminated in consolidation. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation of the financial position and the results of operations for the periods presented have been included. Operating results for the three-month period ended June 27, 2014 are not necessarily indicative of the results that may be expected for the balance of the fiscal year ending March 31, 2015.
	These unaudited condensed consolidated financial statements should be read in conjunction with Management’s Discussion and Analysis and the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2014, filed with the SEC on June 30, 2014.
	Recent Accounting Pronouncements- In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09 – Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. Generally Accepted Accounting Principles (U.S. GAAP). The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required with the revenue recognition process than are required under existing U.S. GAAP.
	The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii)a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of adopting ASU 2014-09 on the consolidated financial statement and has not yet determined the method by which the Company will adopt the standard in fiscal 2018.

Note_2_Stock_Based_Compensatio

Note 2 - Stock Based Compensation	3 Months Ended
	Jun. 27, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 2. Stock Based Compensation
	The Company has three stock equity plans: The 1997 Employee Stock Option Plan, the 2000 Stock Option Plan and the 2007 Equity Incentive Plan. In addition, the Company has requested that its stockholders approve the Company’s 2014 Equity Incentive Plan at the 2014 Annual Stockholders Meeting, which is scheduled for August 22, 2014.
	As of December 30, 2011, no additional awards may be issued under either the 1997 Employee Stock Option Plan or the 2000 Stock Option Plan. There are 2,500,000 shares authorized for issuance under the 2007 Equity Incentive Plan, with 250,095 shares remaining available for future grant.
	Options and restricted stock awards may be granted to employees, officers, directors and consultants. Options typically vest over a period of one to four years and are exercisable up to ten years from the date of issuance. The option exercise price equals the stock’s market price on the date of grant. Restricted stock awards typically vest over a period of six months to four years, and the shares subject to such awards are generally not transferrable until the awards vest.
	The following table summarizes information regarding options outstanding and options exercisable at each of the quarterly periods for the three months ended June 28, 2013 and June 27, 2014, respectively, and the changes during the periods then ended:
			Number of				Weighted			Number of			Weighted
			Options				Average			Shares			Average Exercise
			Outstanding				Exercise Price			Exercisable			Price per Share
			(000’s)				per Share			(000’s)
	Balance as of March 31, 2013			2,392			$	1.66			2,142		$	1.76
	Granted			24			$	0.48
	Exercised			--			$	--
	Expired or forfeited			(114	)		$	1.03
	Balance as of June 28, 2013			2,302			$	1.68			2,099		$	1.76
			Number of				Weighted			Number of			Weighted
			Options				Average			Shares			Average Exercise
			Outstanding				Exercise Price			Exercisable			Price per Share
			(000’s)				per Share			(000’s)
	Balance as of March 31, 2014			2,171			$	1.66			2,017		$	1.75
	Granted			--			$	--
	Exercised			--			$	--
	Expired or forfeited			(36	)		$	2.09
	Balance as of June 27, 2014			2,135			$	1.68			2,031		$	1.7
	Vested & expected to Vest, June 27, 2014			2,105			$	1.67
	Information regarding stock options outstanding as of June 27, 2014 is as follows:
						Options Outstanding
		Price Range				Shares			Weighted			Weighted Average
						(in 000s)			Average			Remaining Life
									Exercise Price
		$	0.44 - $1.25				525		$	0.71			7.24
		$	1.26 - $2.50				1,360		$	1.81			2.94
		$	2.56 - $5.34				250		$	2.83			1.17
						Options Exercisable
		Price Range				Shares			Weighted			Weighted Average
						(in 000s)			Average			Remaining Life
									Exercise Price
		$	0.44 - $1.25				421		$	0.66			7.2
		$	1.26 - $2.50				1,360		$	1.81			2.94
		$	2.56 - $5.34				250		$	2.83			1.17
	As there were no stock options exercised during the three month periods ended June 27, 2014 and June 28, 2013 there was no intrinsic value realized in either period.
	During the first quarter of fiscal 2015, no restricted shares were issued. There were 40,000 restricted shares issued during the first quarter of fiscal 2014. The restricted share transactions are summarized below:
			Shares (000’s)				Weighted Average Grant Date
							Fair Value Per Share
	Unvested, March 31, 2013			128			$	0.87
	Granted			40			$	0.48
	Vested			--			$	--
	Expired or forfeited			(1	)		$	0.76
	Unvested, June 28, 2013			167			$	0.78
			Shares (000’s)				Weighted Average Grant Date
							Fair Value Per Share
	Unvested, March 31, 2014			84			$	0.76
	Granted			--			$	--
	Vested			--			$	--
	Expired or forfeited			(16	)		$	0.5
	Unvested, June 27, 2014			68			$	0.83
	The Company estimates the fair value of stock-based awards utilizing the Black-Scholes pricing model for stock options and using the intrinsic value for restricted stock. The fair value of the awards is amortized as compensation expense on a straight-line basis over the requisite service period of the award, which is generally the vesting period. The Black-Scholes fair value calculations involve significant judgments, assumptions, estimates and complexities that impact the amount of compensation expense to be recorded in current and future periods. The factors include:
		1	The time period that option awards are expected to remain outstanding has been determined based on the average of the original award period and the remaining vesting period. The expected term assumption for awards issued during the three month period ended June 28, 2013 was 6.3 years. As additional evidence develops from the employee’s stock trading history, the expected term assumption will be refined to capture the relevant trends.
		2	The future volatility of the Company’s stock has been estimated based on the weekly stock price during the expected term to the date of the latest stock option grant. The expected volatility assumption for awards issued during the three month period ending June 28, 2013 averaged 68%. As additional evidence develops, the future volatility estimate will be refined to capture the relevant trends.
		3	A dividend yield of zero has been assumed for awards issued during the three month period ended June 28, 2013, based on the Company’s actual past experience and the fact that Company does not anticipate paying a dividend on its shares in the near future.
		4	The Company has based its risk-free interest rate assumption for awards issued during the three month period ended June 28, 2013 on the implied yield available on U.S. Treasury issues with an equivalent expected term, with a rate used of 1.1%.
		5	The forfeiture rate, for awards issued during the three month period ended June 28, 2013, was approximately 22.0%, and was based on the Company’s actual historical forfeiture history.
	The Company’s stock-based compensation expense is classified in the table below:
			Three months ended
		27-Jun-14				June 28, 201312
Cost of Products Sold		$	1,000			$	2,000
Research and Development expense			4,000				5,000
General and Administrative expense			13,000				15,000
Sales and Marketing expense			3,000				7,000
Total Stock Based Compensation		$	21,000			$	29,000
At June 27, 2014, the total stock-based compensation expense related to unvested stock options and restricted shares granted to employees and independent directors under the Company’s stock option plans but not yet recognized was approximately $66,000. This expense will be amortized on a straight-line basis over a weighted-average period of approximately 1.1 years and will be adjusted for subsequent changes in estimated forfeitures.

Note_3_Credit_Risk

Note 3 - Credit Risk	3 Months Ended
	Jun. 27, 2014
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	Note 3. Credit Risk
	Pervasiveness of Estimates and Risk - The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash equivalents and trade accounts receivable.
	Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. API has never experienced any losses related to these balances. At June 27, 2014, approximately $1,163,000 is held in excess of federally insured limits.
	Accounts receivable are unsecured and the Company is at risk to the extent such amounts become uncollectible. The Company performs periodic credit evaluations of its customers’ financial condition and generally does not require collateral. Any unanticipated change in the customers’ credit worthiness or other matters affecting the collectability of amounts due from such customers could have a material effect on the results of operations in the period in which such changes or events occur. As of June 27, 2014 one customer individually comprised 24% of accounts receivable. As of March 31, 2014, one customer individually comprised 19% of accounts receivable. The allowance for doubtful account balance was $20,000 on both June 27, 2014 and March 31, 2014.

Note_4_Detail_of_Certain_Asset

Note 4 - Detail of Certain Asset Accounts	3 Months Ended
	Jun. 27, 2014
Details Of Certain Balance Sheet Accounts Disclosure [Abstract]	'
Details Of Certain Balance Sheet Accounts Disclosure [Text Block]	'
	Note 4. Detail of Certain Asset Accounts
	Cash and Cash Equivalents - The Company considers all highly liquid investments, with an original maturity of three months or less when purchased, to be cash equivalents.
	Inventories - Inventories, which include material, labor and manufacturing overhead, are stated at the lower of cost (on a first in, first out method) or market. Inventories consist of the following at June 27, 2014 and March 31, 2014:
		27-Jun-14			31-Mar-14
	Raw material	$	2,694,000		$	3,093,000
	Work-in-process		1,039,000			954,000
	Finished products		952,000			702,000
	Inventories, net	$	4,685,000		$	4,749,000
	Slow moving and obsolete inventories are reviewed throughout the year to assess whether a cost adjustment is required. Our review of slow moving and obsolete inventory begins with a listing of all inventory items which have not moved regularly within the past 12 months. In addition, any residual inventory, which is customer specific and remaining on hand at the time of contract completion, is included in the list. The complete list of slow moving and obsolete inventory is then reviewed by the production, engineering and/or purchasing departments to identify items that can be utilized in the near future. These items are then excluded from the analysis and the remaining amount of slow-moving and obsolete inventory is then further assessed and a write down is recorded when warranted. Additionally, non-cancelable open purchase orders for parts we are obligated to purchase where demand has been reduced may also be reserved. Impairments for open purchase orders where the market price is lower than the purchase order price are also recorded. The impairments established for excess, slow moving, and obsolete inventory create a new cost basis for those items. The cost basis of these parts is not subsequently increased if the circumstances which led to the impairment change in the future. If a product that had previously been impaired is subsequently sold, the amount of reduced cost basis is reflected as cost of goods sold.
	Intangible Assets - Intangible assets that have definite lives consist of the following (dollars in thousands):
		Weighted		27-Jun-14
		Average
		Lives in		Amortization		Carrying		Accumulated		Intangibles
		Years		Method		Value		Amortization		Net
	Customer list		15	Straight Line		$	190	$	116	$	74
	Trademarks		15	Cash Flow			2,270		1,309		961
	Technology		10	Cash Flow			10,950		10,705		245
	Distribution Rights		7	Straight Line			148		28		120
	Patents pending						603		--		603
	Patents		10	Straight Line			1,335		566		769
	Total Intangibles					$	15,496	$	12,724	$	2,772
		Weighted		31-Mar-14
		Average
		Lives in		Amortization		Carrying		Accumulated		Intangibles
		Years		Method		Value		Amortization		Net
	Customer list		15	Straight Line		$	190	$	113	$	77
	Trademarks		15	Cash Flow			2,270		1,267		1,003
	Technology		10	Cash Flow			10,950		10,672		278
	Distribution Rights		7	Straight Line			148		23		125
	Patents pending						795		--		795
	Patents		10	Straight Line			1,108		444		664
	Total Intangibles					$	15,461	$	12,519	$	2,942
	Amortization expense for the three-month periods ended June 27, 2014 and June 28, 2013 was approximately $205,000 and $250,000, respectively. The current patents held by the Company have remaining useful lives ranging up to 20 years.
	The cash flow method of amortization is based upon management’s estimate of how the intangible asset contributes to our cash flows and best represents the pattern of how the economic benefits of the intangible asset will be consumed or used up. Such amortization is initially derived from the estimated undiscounted cash flows that were used in determining the original fair value of the intangible asset at the acquisition date and is monitored for significant changes in subsequent periods.
	Assuming no impairment to the intangible value, future amortization expense for intangible assets and patents, excluding patents pending, are as follows by fiscal year (in thousands):
	Intangible Assets and Patents
	Remainder of 2015	$	368
	2016		489
	2017		336
	2018		332
	2019		325
	2020 & after		319
	Total	$	2,169
	Patent pending costs of $603,000 are not included in the future amortization chart above. These costs will be amortized beginning the month the patents are granted.

Note_5_Debt

Note 5 - Debt	3 Months Ended
	Jun. 27, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 5. Debt
	Total outstanding debt of the Company as of June 27, 2014 and March 31, 2014 consisted of the following (in thousands):
		27-Jun-14		31-Mar-14
	Bank term loan	$	250	$	306
	Bank line of credit		1,294		2,147
	MEDC/MSF loans		654		654
	Partners for Growth loan, net of debt discount		1,367		1,508
	Capital leases		50		56
	Total	$	3,615	$	4,671
	Bank Debt
	On January 31, 2012, API entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB” and such agreement as amended from time to time, the “SVB Loan Agreement”) and a related Loan and Security Agreement (Ex-IM Loan Facility) with SVB (as amended from time to time, the “SVB Ex-Im Loan Agreement”, and together with the SVB Loan Agreement, the “SVB Loan Agreements”) that provided for a three-year $1 million term loan that, as amended through June 2014, expires in March 2015, and a $5 million line of credit with a $3 million export-import facility sublimit that, as amended through June 2014, expires in June 2016. Subsequent to the execution of the original SVB Loan Agreements, there have been eight amendments that have modified the financial covenants, allowed for the acquisition of substantially all of the operating assets of Silonex, Inc. (“Silonex”), allowed the Company to enter into the loan agreement with Partners for Growth III, L.P. (“PFG” and such agreement as amended from time to time as the “PFG Loan Agreement) as described below and extended the maturity date of the line of credit from January 2014 to June 2016.
	The SVB Loan Agreements as amended contained December 2013 and January 2014 financial covenants that required the Company to maintain a minimum liquidity ratio of 2.25 to 1.00 and a minimum trailing three month adjusted EBITDA, measured monthly of (1) a negative $300,000 for each fiscal month during the period July through October 2013; and (2) $1 for each fiscal month during the period November 2013 through February 2014.
	As of December 27, 2013 and January 24, 2014, the Company was not in compliance with the then existing minimum adjusted EBITDA covenant of $1 for the three months ended December 27, 2013 and January 31, 2014, respectively, and as of January 31, 2014, the Company was also not in compliance with the then existing minimum liquidity ratio of 2.25 to 1.00. In addition, the foregoing defaults triggered the cross-default provisions under each of the SVB Loan Agreements and the loan with PFG under the PFG Loan Agreement. Consequently, under the terms of each agreement, SVB and PFG were both entitled to proceed against the collateral provided as security for the loans issued thereunder upon an event of default subject, in PFG’s case, to any rights that SVB may have in that same collateral.
	On February 10, 2014, API entered into separate Forbearance Agreements with SVB and PFG pursuant to which and subject to certain exceptions, each of SVB and PFG agreed not to proceed against the collateral securing their respective loans until February 28, 2014. On March 5, 2014, the Company entered into separate amendment agreements with SVB and PFG where, among other things, (i) SVB agreed to extend the maturity date of the Company’s $5 million line of credit to May 31, 2014; (ii) the minimum trailing three month adjusted EBITDA covenant was reset to a negative $1.2 million for the fiscal month ended February 28, 2014, a negative $800,000 for the fiscal month ended March 31, 2014, a negative $600,000 for the fiscal month ended April 30, 2014 and a positive $1 for the fiscal month ending May 31, 2014; (iii) the existing minimum liquidity ratio covenant was reset to 1.30 to 1.00 as of February 28, 2014, and 2.25 to 1.00 for each month thereafter through May 2014; and (iv) each of SVB and PFG waived the existing defaults. In addition to the payment of an amendment fee, the Company agreed to pay each of SVB and PFG additional fees of up to $50,000 and $75,000, respectively, no later than May 31, 2014 (the “Tail Fees”).
	On April 30, 2014, API entered into separate amendment agreements with SVB and PFG where, among other things, (i) SVB agreed to extend the maturity date of the $5 million line of credit to July 31, 2014; (ii) the trailing three month adjusted EBITDA covenant was reset to a negative $800,000 for the fiscal month ended March 31, 2014, a negative $600,000 for the fiscal month ended April 30, 2014, a negative $250,000 for the fiscal months ending May 31, 2014 and June 30, 2014 and a positive $1 for the fiscal month ending July 31, 2014; and (iii) the existing minimum liquidity ratio covenant was reset to 1.30 to 1.00 as of March 31, 2014 through May 31, 2014, and 2.00 to 1.00 for each month thereafter through July 2014. In addition to the payment of an amendment fee, the Company agreed to pay each of SVB and PFG their respective Tail Fee and, commencing with the month ended May 31, 2014, an additional fee of $15,000 and $20,000, respectively, for each month that the liquidity ratio is less than 2.00 to 1.00 as of the last day of the month under measurement.
	On June 6, 2014, API received approximately $2,657,000 in proceeds before expenses from a secondary placement of 5,391,304 shares of Class A Common Stock through a firm underwriting by B Riley & Co., LLC. On June 10, 2014, the underwriter exercised the option on an additional 808,696 shares of Class A Common Stock for proceeds before expenses of $398,606. The net proceeds were used to pay down the existing line of credit with SVB and certain related fees. On June 20, 2014, API signed separate amendments with SVB and PFG where, among other things, (i) SVB agreed to extend the maturity date of the Company’s line of credit to June 2016, (ii) all parties agreed to a six month trailing adjusted EBTIDA covenant, measured at each fiscal month end, of negative $850,000 through June 2014, negative $300,000 for July through September 2014, a positive $1 for October through December 2014 and $100,000 each month thereafter subject to reset upon the submission of the fiscal 2016 budget but no lower than $100,000 on a rolling six month basis, (iii) all parties agreed to adjust the minimum liquidity ratio, as defined, to be 1.30 to 1.00 for months ending prior to June 2014 and 2.00 to 1.00 for all months on or after June 2014 as measured at each month end, and (iv) SVB restored an interest rate matrix based on the covenant performance that results in an interest rate on the line of credit to range from prime rate plus 50 basis points up to prime rate plus 400 basis points and an interest rate on the term loan to range from prime plus 75 basis points up to prime plus 450 basis points. The agreements confirmed the obligation to pay the previously agreed Tail fees of $50,000 and $75,000 to SVB and PFG respectively, associated attorney fees for the amendment, but waived the added tail fees for May 2014 of $15,000 and $20,000 respectively.
	The interest rates on the SVB term loan and line of credit as of June 27, 2014 were 6.50% and 6.00%, respectively. The Company had approximately $1.3 million outstanding on the SVB line of credit with approximately $3.1 million in borrowing capacity as of June 27, 2014.
	The EX-IM Loan Facility is guaranteed by the API’s subsidiaries and all borrowings under the SVB Loan Agreements are secured by a first priority security interest granted to SVB over substantially all of the Company’s respective assets. As of June 27, 2014, the Company is and expects to remain in compliance with the related liquidity and adjusted EBITDA covenant with SVB. The SVB term loan expires in March 2015 and the line of credit expires in June 2016.
	Total interest payments made to the bank during the three months ended June 27, 2014 and June 28, 2013 were approximately $38,000 and $12,000, respectively.
	Partners for Growth Secured Debt
	On February 8, 2013, API entered into a $2.5 million secured Loan and Security Agreement with PFG that is subordinated to the SVB Loan Agreements. Pursuant to the terms of the agreement, the Company is obligated to make monthly principal payments of $59,524, plus accrued interest at 11.75% through maturity in August 2016. As part of the consideration for and as a closing condition to the PFG Loan Agreement, the Company agreed to grant PFG and certain of its affiliates warrants to purchase up to 1,195,000 shares of the Company’s Class A Stock (the “Warrants”) in a private placement pursuant to Section 4(a)(2) of the Securities Act. 995,000 of the shares issuable under the Warrants were granted at an initial strike price equal to $0.50 per share (the “Tier 1 Warrants”), and the remaining 200,000 shares issuable under the Warrants were granted at an initial strike price equal to $1.00 per share (“$1.00 Warrants”).
	The Warrants contain full-ratchet anti-dilution provisions that will result in proportional adjustments to the exercise price and the number of shares issuable under the PFG Warrant Agreements in the event that the Company conducts a stock split, subdivision, stock dividend or combination, or similar transaction. The PFG Warrant Agreements also include a net exercise provision pursuant to which warrant holders will receive the number of shares equal to (x) the product of (A) the number of Warrants exercised multiplied by (B) the difference between (1) the fair market value of a share of Class A Stock (with fair value generally being equal to the highest closing price of the Company’s Class A Stock during the 45 consecutive trading days prior to the date of exercise) and (2) the strike price of the Warrant, (y) divided by the fair market value of a share of Class A Stock. In addition, in the event the Company is acquired, liquidates, conducts a public offering, or the Warrants expire, each warrant holder will have the right to “put” its Warrants to the Company in exchange for a per share cash payment that varies with the number of shares issuable under each Warrant, but in the aggregate will not exceed $250,000.
	The PFG Loan Agreements as amended through December 2013 and January 2014, contained financial covenants that required the Company to maintain a minimum liquidity ratio of 2.25 to 1.00 and a minimum trailing three month adjusted EBITDA, measured monthly of (1) a negative $300,000 for each fiscal month during the period July through October 2013; and (2) $1 for each fiscal month during the period November 2013 through February 2014.
	As of December 27, 2013 and January 24, 2014, API was not in compliance with then existing adjusted minimum EBITDA covenant of $1 for the three months ended December 27, 2013 and January 24, 2014, respectively, and as of January 24, 2014, API was also not in compliance with the then existing minimum liquidity ratio of 2.25 to 1.00. In addition, the foregoing defaults triggered the cross-default provisions under each of the SVB Loan Agreements and the loan with PFG. Consequently, under the terms of each agreement, SVB and PFG were both entitled to proceed against the collateral provided as security for the loans issued thereunder upon an event of default subject, in PFG’s case, to any rights that SVB may have in that same collateral.
	On February 10, 2014, API entered into separate Forbearance Agreements with SVB and PFG pursuant to which and subject to certain exceptions, each of SVB and PFG agreed not to proceed against the collateral securing their respective loans until February 28, 2014. On March 5, 2014, the Company entered into separate amendment agreements with SVB and PFG where, among other things, the minimum trailing three month adjusted EBITDA covenant was reset to a negative $1.2 million for the fiscal month ended February 28, 2014, a negative $800,000 for the fiscal month ended March 31, 2014, a negative $600,000 for the fiscal month ended April 30, 2014 and a positive $1 for the fiscal month ending May 31, 2014; the existing minimum liquidity ratio covenant was reset to 1.30 to 1.00 as of February 28, 2014, and 2.25 to 1.00 for each month thereafter through May 2014; and each of SVB and PFG waived the existing defaults. In addition to the payment of an amendment fee, the Company agreed to pay each of SVB and PFG additional fees of up to $50,000 and $75,000, respectively, no later than May 31, 2014 (the “Tail Fees”).
	On April 30, 2014, API entered into separate amendment agreements with SVB and PFG where, among other things the trailing minimum three month adjusted EBITDA covenant was reset to a negative $800,000 for the fiscal month ended March 31, 2014, a negative $600,000 for the fiscal month ended April 30, 2014, a negative $250,000 for the fiscal months ending May 31, 2014 and June 30, 2014 and a positive $1 for the fiscal month ending July 31, 2014; and the existing minimum liquidity ratio covenant was reset to 1.30 to 1.00 as of March 31, 2014 through May 31, 2014, and 2.00 to 1.00 for each month thereafter through July 2014. In addition to the payment of an amendment fee, the Company agreed to pay each of SVB and PFG their respective Tail Fee and, commencing with the month ended May 31, 2014, an additional fee of $15,000 and $20,000, respectively, for each month that the liquidity ratio is less than 2.00 to 1.00 as of the last day of the month under measurement.
	On June 20, 2014, API signed a separate amendments with SVB and PFG where, among other things, both parties agreed to a minimum six month trailing adjusted EBTIDA covenant, measured at each fiscal month end, of negative $850,000 through June 2014, negative $300,000 for July through September 2014, a positive $1 for October through December 2014 and $100,000 each month thereafter subject to reset upon the submission of the fiscal 2016 budget but no lower than $100,000 on a rolling six month basis, both parties agreed to adjust the minimum liquidity ratio, as defined, to be 1.30 to 1.00 for months ending prior to June 2014 and 2.00 to 1.00 for all months on or after June 2014 as measured at each month end. The agreements confirmed the obligation to pay the previously agreed Tail fees of $50,000 and $75,000 to SVB and PFG respectively, associated attorney fees for the amendment, but waived the added tail fees for May of $15,000 for SVB and $20,000 for PFG.
	As of June 27, 2014, the Company is and expects to remain in compliance with the related liquidity and adjusted EBITDA covenant with PFG, which were substantially the same as with SVB as of that date.
	The Company determined the fair value of the warrant as of the issuance date to be $434,000. Pursuant to the accounting literature, a debt discount and a warrant liability were established as of the issuance date with the debt discount amortized over the life of the loan on an effective interest method. As of June 27, 2014, there was $179,000 in remaining unamortized debt discount offset against the PFG long term debt principal. See Note 6 to the Consolidated Financial Statements for additional information on the PFG warrants.
	Total interest payments made to PFG during the years ended June 27, 2014 and June 28, 2013 were approximately $50,000 and $71,000, respectively.
	MEDC/MSF Loans
	In fiscal years 2005 and 2006, we entered into two unsecured loan agreements that are currently held by the Michigan Economic Development Corporation (“MEDC” and such agreement the “MEDC Loan Agreement”) and a MEDC affiliate, the Michigan Strategic Fund (“MSF” and such agreement the “MSF Loan Agreement”) pursuant to which we borrowed an aggregate of amount of $2.2 million. As amended, payments on the approximately $327,000 in principal outstanding, as of June 27, 2014, under each of the MEDC Loan Agreement and MSF Loan Agreement are deferred until they mature on December 1, 2014 and November 1, 2014, respectively, at which time the entire remaining balance under each loan agreement becomes due and payable. The interest rate under both of the loans was 5.00% as of June 27, 2014.
	Interest payments made to the MEDC/MSF were approximately $8,000 and $9,000 during the three months ended June 27, 2014 and June 28, 2013, respectively.
	Capital Leases
	During fiscal 2014, the Company purchased certain equipment through several capital leases with monthly principal payments of $1,700 plus interest with some maturities extending to 2019. The leases are collateralized by the associated equipment.
	Interest payments made to the lessors for the three months ended June 27, 2014 and June 28, 2013 were $1,000 and zero, respectively.

Note_6_Stockholders_Equity

Note 6 - Stockholders' Equity	3 Months Ended
	Jun. 27, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 6. Stockholders’ Equity
	Equity Issuance
	On May 30, 2014, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with B. Riley & Co., LLC, (the “Underwriter”) as sole underwriter for the offer and sale in a firm commitment underwritten public offering of 5,391,304 shares of the Company’s Common Stock at a price to the public of $0.530 per share ($0.493 per share, net of underwriting discounts) (the “Offering”). Pursuant to the Underwriting Agreement, the Company also (i) granted to the Underwriter a 30-day option to purchase up to an additional 808,696 shares of Common Stock to cover over-allotments, if any, at the same price and (ii) agreed to reimburse the Underwriter for certain of its out-of-pocket expenses.
	The Offering was (i) made pursuant to a prospectus supplement dated May 30, 2014, and an accompanying prospectus dated May 5, 2014 pursuant to the Company’s existing shelf registration statement on Form S-3 (File No. 333-195689), which was filed with the Securities and Exchange Commission on May 5, 2014 and declared effective by the Commission on May 12, 2014; and (ii) subject to the satisfaction of customary closing conditions for transactions of this nature including, but not limited to, NYSE MKT approval of the Company’s additional listing application to list the Common Stock issued accordance with the Underwriting Agreement on NYSE MKT (the “Additional Listing Application”). On June 5, 2014, NYSE MKT approved the Additional Listing Application and the Offering closed on June 6, 2014, when the Company and Underwriter satisfied the other closing conditions. The Underwriter on June 9, 2014 provided notice to the Company of their intent to purchase the over allotment shares and the offering closed on June 12, 2014.
	The net proceeds to the Company from selling 6,200,000 shares of the Company’s Common Stock in the Offering, after underwriting discounts and estimated transaction expenses, were approximately $2.9 million. The Company has used the proceeds to pay down the existing line of credit with SVB.
	Warrants
	At March 31, 2014 and June 27, 2014, the Company had the following warrants outstanding and exercisable:
			Shares			Exercise Price
			(000’s)
	2010 Warrants			267		$	1.242
	PFG Warrants			995		$	0.5
	PFG Warrants			200		$	1
	Total			1,462
	On November 29, 2010, the Company issued 267,196 warrants to Robin Risser and Steve Williamson (the 2010 Warrants). Each 2010 Warrant is exercisable over a five year period for one share of the Company’s Class A Common Stock at an exercise price subject to adjustment, based on a formula in the warrant agreements, if Common Stock is issued in the future below $1.404. Future adjustments cannot reduce the exercise price below $1.17. Given the issuance in June 2014 of approximately 6.2 million shares at a price of $0.493 per share, a price reset was triggered to the 2010 Warrants and the new exercise price became $1.242. As a result of the exercise price reset feature, the fair values of the warrants are recorded as a liability with changes in values flowing through the Consolidated Statements of Operations.
	As described in Note 5, during February 2013, the Company issued warrants to PFG to purchase 1,195,000 shares of the Company’s Class A Common Stock. The PFG warrants are exercisable over a five year period with 995,000 shares at strike price of $0.50 per share and another 200,000 shares with a strike price of $1.00 per share. The PFG warrant agreement contains a provision allowing the warrant to be put back to the Company under certain circumstances. Given this feature, the fair values of the warrants are recorded as a liability with changes in values flowing through the Consolidated Statements of Operations.
	For the three months ended June 27, 2014, the Company recorded income of $45,000 for the change in fair value of the warrant liability. For the three months ended June 28, 2013, the Company recorded expense of $196,000. The fair value of the warrant liability outstanding was approximately $364,000 and $409,000 as of June 27, 2014 and March 31, 2014, respectively.
	The fair value of the warrant liability was estimated using the Monte Carlo option pricing model using the following assumptions:
		27-Jun-14		31-Mar-14
		PFG Warrants	2010 Warrants	PFG Warrants	2010 Warrants
	Contractual term in years	3.6	1.4	3.9	1.7
	Volatility	68.90%	73.30%	65.60%	69.50%
	Expected dividend	--	--	--	--
	Risk-free interest rate	1.12%	0.25%	1.25%	0.34%
	Expected volatility is based primarily on historical volatility using the weekly stock price for the most recent period equivalent to the term of the warrants. A dividend yield of zero has been assumed based on the Company’s actual past experience and the fact that the Company does not anticipate paying a dividend on its shares in the future. The Company has based its risk-free interest on the implied yield available on U.S. Treasury issues with equivalent contractual term.
	When a warrant may have different share exercise assumptions such as those issued in February 2013 to PFG and affiliates, the Company weighs various values based on the estimated probability of each outcome as of the valuation date.
	The following chart represents the activity in the Company’s Level 3 warrants during the three months ended June 27, 2014 and the year ended March 31, 2014.
			Three months Ended June 27, 2014			Year Ended March 31, 2014
	Level 3 Warrants, beginning of period		$	409,000		$	292,000
	Addition – PFG Warrants, initial fair value			--			--
	Change in fair value of warrant liability			(45,000	)		117,000
	Level 3 Warrants, end of period		$	364,000		$	409,000
	MEDC Put Option
	In May 2010, the Company entered into a debt conversion agreement with the MEDC whereby the MEDC converted the accrued and unpaid interest as of November 30, 2009 totaling $562,336 into 1,041,363 unregistered shares of our Class A Common Stock at a price per share of $0.54 (market value of the stock on the day of conversion). In addition, the Company granted MEDC a put option to sell back the shares received pursuant to the debt conversion agreement in the event of a trigger event as defined in the debt conversion agreement. Given the conditions under which the put may be exercised are in the control of the Company, a liability for the fair value has not been recorded.

Note_7_Earnings_Per_Share

Note 7 - Earnings Per Share	3 Months Ended
	Jun. 27, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Note 7. Earnings Per Share
	The Company’s net earnings per share calculations are in accordance with FASB ASC 260-10. Accordingly, basic earnings (loss) per share are computed by dividing net earnings (loss) by the weighted average number of shares outstanding for each year. The calculation of income (loss) per share is as follows:
		Three months ended
	Basic and Diluted	27-Jun-14			28-Jun-13
	Weighted Average Basic Shares Outstanding		32,642,000			31,198,000
	Dilutive effect of Stock Options and Warrants		--			--
	Weighted Average Diluted Shares Outstanding		32,642,000			31,198,000
	Net loss	$	(268,000	)	$	(925,000	)
	Basic loss per share	$	(0.01	)	$	(0.03	)
	Diluted loss per share	$	(0.01	)	$	(0.03	)
	The dilutive effect of stock options for the three-month periods ended June 27, 2014 and June 28, 2013 was not included in the calculation of diluted loss per share because to do so would have had an anti-dilutive effect as the Company had a net loss for the respective periods.

Note_8_Fair_Value_of_Financial

Note 8 - Fair Value of Financial Instruments	3 Months Ended
	Jun. 27, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	Note 8. Fair Value of Financial Instruments
	The carrying value of all financial instruments potentially subject to valuation risk (principally consisting of cash equivalents, accounts receivable, accounts payable, MEDC/MSF debt and SVB bank debt) approximates the fair value based upon the short-term nature of these instruments. In the case of the PFG debt, the carrying value approximates fair value based upon prevailing interest rates and terms available to the Company.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	3 Months Ended
	Jun. 27, 2014
Accounting Policies [Abstract]	'
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements- In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09 – Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. Generally Accepted Accounting Principles (U.S. GAAP). The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required with the revenue recognition process than are required under existing U.S. GAAP.
	The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii)a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of adopting ASU 2014-09 on the consolidated financial statement and has not yet determined the method by which the Company will adopt the standard in fiscal 2018.

Note_2_Stock_Based_Compensatio1

Note 2 - Stock Based Compensation (Tables)	3 Months Ended
	Jun. 27, 2014
Note 2 - Stock Based Compensation (Tables) [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
			Number of				Weighted			Number of			Weighted
			Options				Average			Shares			Average Exercise
			Outstanding				Exercise Price			Exercisable			Price per Share
			(000’s)				per Share			(000’s)
	Balance as of March 31, 2013			2,392			$	1.66			2,142		$	1.76
	Granted			24			$	0.48
	Exercised			--			$	--
	Expired or forfeited			(114	)		$	1.03
	Balance as of June 28, 2013			2,302			$	1.68			2,099		$	1.76
			Number of				Weighted			Number of			Weighted
			Options				Average			Shares			Average Exercise
			Outstanding				Exercise Price			Exercisable			Price per Share
			(000’s)				per Share			(000’s)
	Balance as of March 31, 2014			2,171			$	1.66			2,017		$	1.75
	Granted			--			$	--
	Exercised			--			$	--
	Expired or forfeited			(36	)		$	2.09
	Balance as of June 27, 2014			2,135			$	1.68			2,031		$	1.7
	Vested & expected to Vest, June 27, 2014			2,105			$	1.67
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
						Options Outstanding
		Price Range				Shares			Weighted			Weighted Average
						(in 000s)			Average			Remaining Life
									Exercise Price
		$	0.44 - $1.25				525		$	0.71			7.24
		$	1.26 - $2.50				1,360		$	1.81			2.94
		$	2.56 - $5.34				250		$	2.83			1.17
						Options Exercisable
		Price Range				Shares			Weighted			Weighted Average
						(in 000s)			Average			Remaining Life
									Exercise Price
		$	0.44 - $1.25				421		$	0.66			7.2
		$	1.26 - $2.50				1,360		$	1.81			2.94
		$	2.56 - $5.34				250		$	2.83			1.17
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
			Three months ended
			27-Jun-14				June 28, 201312
	Cost of Products Sold		$	1,000			$	2,000
	Research and Development expense			4,000				5,000
	General and Administrative expense			13,000				15,000
	Sales and Marketing expense			3,000				7,000
	Total Stock Based Compensation		$	21,000			$	29,000
Restricted Stock [Member]	'
Note 2 - Stock Based Compensation (Tables) [Line Items]	'
Schedule of Nonvested Share Activity [Table Text Block]	'
			Shares (000’s)				Weighted Average Grant Date
							Fair Value Per Share
	Unvested, March 31, 2013			128			$	0.87
	Granted			40			$	0.48
	Vested			--			$	--
	Expired or forfeited			(1	)		$	0.76
	Unvested, June 28, 2013			167			$	0.78
			Shares (000’s)				Weighted Average Grant Date
							Fair Value Per Share
	Unvested, March 31, 2014			84			$	0.76
	Granted			--			$	--
	Vested			--			$	--
	Expired or forfeited			(16	)		$	0.5
	Unvested, June 27, 2014			68			$	0.83

Note_4_Detail_of_Certain_Asset1

Note 4 - Detail of Certain Asset Accounts (Tables)	3 Months Ended
	Jun. 27, 2014
Details Of Certain Balance Sheet Accounts Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		27-Jun-14			31-Mar-14
	Raw material	$	2,694,000		$	3,093,000
	Work-in-process		1,039,000			954,000
	Finished products		952,000			702,000
	Inventories, net	$	4,685,000		$	4,749,000
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
		Weighted		27-Jun-14
		Average
		Lives in		Amortization		Carrying		Accumulated		Intangibles
		Years		Method		Value		Amortization		Net
	Customer list		15	Straight Line		$	190	$	116	$	74
	Trademarks		15	Cash Flow			2,270		1,309		961
	Technology		10	Cash Flow			10,950		10,705		245
	Distribution Rights		7	Straight Line			148		28		120
	Patents pending						603		--		603
	Patents		10	Straight Line			1,335		566		769
	Total Intangibles					$	15,496	$	12,724	$	2,772
		Weighted		31-Mar-14
		Average
		Lives in		Amortization		Carrying		Accumulated		Intangibles
		Years		Method		Value		Amortization		Net
	Customer list		15	Straight Line		$	190	$	113	$	77
	Trademarks		15	Cash Flow			2,270		1,267		1,003
	Technology		10	Cash Flow			10,950		10,672		278
	Distribution Rights		7	Straight Line			148		23		125
	Patents pending						795		--		795
	Patents		10	Straight Line			1,108		444		664
	Total Intangibles					$	15,461	$	12,519	$	2,942
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Intangible Assets and Patents
	Remainder of 2015	$	368
	2016		489
	2017		336
	2018		332
	2019		325
	2020 & after		319
	Total	$	2,169

Note_5_Debt_Tables

Note 5 - Debt (Tables)	3 Months Ended
	Jun. 27, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
		27-Jun-14		31-Mar-14
	Bank term loan	$	250	$	306
	Bank line of credit		1,294		2,147
	MEDC/MSF loans		654		654
	Partners for Growth loan, net of debt discount		1,367		1,508
	Capital leases		50		56
	Total	$	3,615	$	4,671

Note_6_Stockholders_Equity_Tab

Note 6 - Stockholders' Equity (Tables)	3 Months Ended
	Jun. 27, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
			Shares			Exercise Price
			(000’s)
	2010 Warrants			267		$	1.242
	PFG Warrants			995		$	0.5
	PFG Warrants			200		$	1
	Total			1,462
Fair Value, Option, Quantitative Disclosures [Table Text Block]	'
		27-Jun-14		31-Mar-14
		PFG Warrants	2010 Warrants	PFG Warrants	2010 Warrants
	Contractual term in years	3.6	1.4	3.9	1.7
	Volatility	68.90%	73.30%	65.60%	69.50%
	Expected dividend	--	--	--	--
	Risk-free interest rate	1.12%	0.25%	1.25%	0.34%
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
			Three months Ended June 27, 2014			Year Ended March 31, 2014
	Level 3 Warrants, beginning of period		$	409,000		$	292,000
	Addition – PFG Warrants, initial fair value			--			--
	Change in fair value of warrant liability			(45,000	)		117,000
	Level 3 Warrants, end of period		$	364,000		$	409,000

Note_7_Earnings_Per_Share_Tabl

Note 7 - Earnings Per Share (Tables)	3 Months Ended
	Jun. 27, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
		Three months ended
	Basic and Diluted	27-Jun-14			28-Jun-13
	Weighted Average Basic Shares Outstanding		32,642,000			31,198,000
	Dilutive effect of Stock Options and Warrants		--			--
	Weighted Average Diluted Shares Outstanding		32,642,000			31,198,000
	Net loss	$	(268,000	)	$	(925,000	)
	Basic loss per share	$	(0.01	)	$	(0.03	)
	Diluted loss per share	$	(0.01	)	$	(0.03	)

Note_1_Basis_of_Presentation_D

Note 1 - Basis of Presentation (Details)	3 Months Ended
	Jun. 27, 2014
Disclosure Text Block [Abstract]	'
Number Of Facilities	2

Note_2_Stock_Based_Compensatio2

Note 2 - Stock Based Compensation (Details) (USD $)	3 Months Ended						9 Months Ended
	Jun. 27, 2014	Jun. 28, 2013	Jun. 28, 2013	Jun. 27, 2014	Jun. 27, 2014	Jun. 28, 2013	Dec. 27, 2013	Dec. 27, 2013	Dec. 27, 2013	Jun. 27, 2014
			Employee Stock Option [Member]	Employee Stock Option [Member]	Employee Stock Option [Member]	Restricted Stock [Member]	Restricted Stock [Member]	Restricted Stock [Member]	Restricted Stock [Member]	2007 Equity Incentive Plan [Member]
				Minimum [Member]	Maximum [Member]			Minimum [Member]	Maximum [Member]
Note 2 - Stock Based Compensation (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	'	'	'	'	'	'	'	'	'	2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	'	'	'	'	'	'	'	250,095
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'1 year	'4 years	'	'	'6 months	'4 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	'	'	'	'	'10 years	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0	0	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$0	$0	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	'	40,000	'	'	'	40,000	0	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	'	'	'6 years 109 days	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	'	'	68.00%	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	'	'	0.00%	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	'	'	1.10%	'	'	'	'	'	'	'
Share Based Compensation Arrangement By Share Based PaymentAwardFairValueAssumptionsExpectedForfeitures	'	'	22.00%	'	'	'	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$66,000	'	'	'	'	'	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'1 year 36 days	'	'	'	'	'	'	'	'	'

Note_2_Stock_Based_Compensatio3

Note 2 - Stock Based Compensation (Details) - Summary of Options Outstanding and Options Exercisable, Quarterly (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 27, 2014	Jun. 28, 2013
Summary of Options Outstanding and Options Exercisable, Quarterly [Abstract]	'	'
Balance	2,171	2,392
Balance	$1.66	$1.66
Balance	2,017	2,142
Balance	$1.75	$1.76
Granted	'	24
Granted	'	$0.48
Expired or forfeited	-36	-114
Expired or forfeited	$2.09	$1.03
Balance	2,135	2,302
Balance	$1.68	$1.68
Balance	2,031	2,099
Balance	$1.70	$1.76
Vested & expected to Vest, June 27, 2014	2,105	'
Vested & expected to Vest, June 27, 2014	$1.67	'

Note_2_Stock_Based_Compensatio4

Note 2 - Stock Based Compensation (Details) - Options Outstanding and Options Exercisable (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 27, 2014
Range 1 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Price Range, Lower range	$0.44
Options Outstanding, Price Range, Upper range	$1.25
Options Outstanding, Shares (in Shares)	525
Options Outstanding, Weighted Average Exercise Price	$0.71
Options Outstanding, Weighted Average Remaining Life	'7 years 87 days
Options Exercisable, Price Range, Lower range	$0.44
Options Exercisable, Price Range, Upper range	$1.25
Options Exercisable, Shares (in Shares)	421
Options Exercisable, Weighted Average Exercise Price	$0.66
Options Exercisable, Weighted Average Remaining Life	'7 years 73 days
Range 2 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Price Range, Lower range	$1.26
Options Outstanding, Price Range, Upper range	$2.50
Options Outstanding, Shares (in Shares)	1,360
Options Outstanding, Weighted Average Exercise Price	$1.81
Options Outstanding, Weighted Average Remaining Life	'2 years 343 days
Options Exercisable, Price Range, Lower range	$1.26
Options Exercisable, Price Range, Upper range	$2.50
Options Exercisable, Shares (in Shares)	1,360
Options Exercisable, Weighted Average Exercise Price	$1.81
Options Exercisable, Weighted Average Remaining Life	'2 years 343 days
Range 3 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Price Range, Lower range	$2.56
Options Outstanding, Price Range, Upper range	$5.34
Options Outstanding, Shares (in Shares)	250
Options Outstanding, Weighted Average Exercise Price	$2.83
Options Outstanding, Weighted Average Remaining Life	'1 year 62 days
Options Exercisable, Price Range, Lower range	$2.56
Options Exercisable, Price Range, Upper range	$5.34
Options Exercisable, Shares (in Shares)	250
Options Exercisable, Weighted Average Exercise Price	$2.83
Options Exercisable, Weighted Average Remaining Life	'1 year 62 days

Note_2_Stock_Based_Compensatio5

Note 2 - Stock Based Compensation (Details) - Restricted Share Transactions (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 27, 2014	Jun. 28, 2013
Restricted Share Transactions [Abstract]	'	'
Unvested	84	128
Unvested	$0.76	$0.87
Unvested	68	167
Unvested	$0.83	$0.78
Granted	'	40
Granted	'	$0.48
Expired or forfeited	-16	-1
Expired or forfeited	$0.50	$0.76

Note_2_Stock_Based_Compensatio6

Note 2 - Stock Based Compensation (Details) - Summary of Stock-based Compensation Expense (USD $)	3 Months Ended
	Jun. 27, 2014	Jun. 28, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'
Stock based compensation expense	$21,000	$29,000
Cost of Sales [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'
Stock based compensation expense	1,000	2,000
Research and Development Expense [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'
Stock based compensation expense	4,000	5,000
General and Administrative Expense [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'
Stock based compensation expense	13,000	15,000
Selling and Marketing Expense [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'
Stock based compensation expense	$3,000	$7,000

Note_3_Credit_Risk_Details

Note 3 - Credit Risk (Details) (USD $)	3 Months Ended	12 Months Ended
	Jun. 27, 2014	Mar. 31, 2014
Note 3 - Credit Risk (Details) [Line Items]	'	'
Cash, Uninsured Amount	1,163,000	'
Allowance for Doubtful Accounts Receivable	20,000	20,000
Accounts Receivable [Member] | Customer Concentration Risk [Member]	'	'
Note 3 - Credit Risk (Details) [Line Items]	'	'
Concentration Risk, Customer	'one	'one
Concentration Risk, Percentage	24.00%	19.00%

Note_4_Detail_of_Certain_Asset2

Note 4 - Detail of Certain Asset Accounts (Details) (USD $)	3 Months Ended			3 Months Ended	12 Months Ended	3 Months Ended
	Jun. 27, 2014	Jun. 28, 2013	Mar. 31, 2014	Jun. 27, 2014	Mar. 31, 2014	Jun. 27, 2014	Jun. 27, 2014	Mar. 31, 2014
				Patents [Member]	Patents [Member]	Patents [Member]	Other Intangible Assets [Member]	Other Intangible Assets [Member]
						Maximum [Member]
Note 4 - Detail of Certain Asset Accounts (Details) [Line Items]	'	'	'	'	'	'	'	'
Amortization of Intangible Assets	$205,000	$250,000	'	'	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'10 years	'10 years	'20 years	'	'
Finite-Lived Intangible Assets, Gross	$15,496,000	'	$15,461,000	$1,335,000	$1,108,000	'	$603,000	$795,000

Note_4_Detail_of_Certain_Asset3

Note 4 - Detail of Certain Asset Accounts (Details) - Inventories (USD $)	Jun. 27, 2014	Mar. 31, 2014
Inventories [Abstract]	'	'
Raw material	$2,694,000	$3,093,000
Work-in-process	1,039,000	954,000
Finished products	952,000	702,000
Inventories, net	$4,685,000	$4,749,000

Note_4_Detail_of_Certain_Asset4

Note 4 - Detail of Certain Asset Accounts (Details) - Intangible Assets (USD $)	3 Months Ended	12 Months Ended
	Jun. 27, 2014	Mar. 31, 2014
Finite-Lived Intangible Assets [Line Items]	'	'
Carrying Value	$15,496,000	$15,461,000
Accumulated Amortization	12,724,000	12,519,000
Intangibles Net	2,772,000	2,942,000
Customer Lists [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Weighted Average Lives in Years	'15 years	'15 years
Amortization Method	'Straight Line	'Straight Line
Carrying Value	190,000	190,000
Accumulated Amortization	116,000	113,000
Intangibles Net	74,000	77,000
Trademarks [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Weighted Average Lives in Years	'15 years	'15 years
Amortization Method	'Cash Flow	'Cash Flow
Carrying Value	2,270,000	2,270,000
Accumulated Amortization	1,309,000	1,267,000
Intangibles Net	961,000	1,003,000
Unpatented Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Weighted Average Lives in Years	'10 years	'10 years
Amortization Method	'Cash Flow	'Cash Flow
Carrying Value	10,950,000	10,950,000
Accumulated Amortization	10,705,000	10,672,000
Intangibles Net	245,000	278,000
Distribution Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Weighted Average Lives in Years	'7 years	'7 years
Amortization Method	'Straight Line	'Straight Line
Carrying Value	148,000	148,000
Accumulated Amortization	28,000	23,000
Intangibles Net	120,000	125,000
Other Intangible Assets [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Carrying Value	603,000	795,000
Intangibles Net	603,000	795,000
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Weighted Average Lives in Years	'10 years	'10 years
Amortization Method	'Straight Line	'Straight Line
Carrying Value	1,335,000	1,108,000
Accumulated Amortization	566,000	444,000
Intangibles Net	$769,000	$664,000

Note_4_Detail_of_Certain_Asset5

Note 4 - Detail of Certain Asset Accounts (Details) - Future Amoritization Expenses (USD $)	Jun. 27, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Note 4 - Detail of Certain Asset Accounts (Details) - Future Amoritization Expenses [Line Items]	'	'
Total	$2,772	$2,942
Excluding Patents Pending [Member]	'	'
Note 4 - Detail of Certain Asset Accounts (Details) - Future Amoritization Expenses [Line Items]	'	'
Remainder of 2015	368	'
2016	489	'
2017	336	'
2018	332	'
2019	325	'
2020 & after	319	'
Total	$2,169	'

Note_5_Debt_Details

Note 5 - Debt (Details) (USD $)

3 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

3 Months Ended

Jun. 27, 2014

Jun. 28, 2013

Mar. 31, 2014

Jun. 06, 2014

Jun. 10, 2014

Jun. 12, 2014

Feb. 28, 2013

Feb. 08, 2013

Feb. 28, 2013

Feb. 08, 2013

Feb. 28, 2013

Feb. 08, 2013

Feb. 14, 2013

Feb. 08, 2013

Jun. 27, 2014

Jun. 27, 2014

Jun. 20, 2014

Jun. 20, 2014

Jan. 31, 2012

Jun. 28, 2013

Jun. 28, 2013

Jun. 27, 2014

Jun. 20, 2014

Jun. 20, 2014

Jun. 27, 2014

Jun. 20, 2014

Jun. 20, 2014

Jun. 27, 2014

Jun. 28, 2013

Mar. 31, 2014

Jun. 28, 2013

Jan. 31, 2012

Jan. 31, 2012

Jun. 27, 2014

Jun. 28, 2013

Apr. 30, 2014

Feb. 10, 2014

Jun. 20, 2014

Feb. 10, 2014

Apr. 30, 2014

Jun. 20, 2014

Feb. 10, 2014

Apr. 30, 2014

Jun. 20, 2014

Feb. 10, 2014

Apr. 30, 2014

Jun. 20, 2014

Feb. 10, 2014

Apr. 30, 2014

Apr. 30, 2014

Jan. 31, 2014

Jan. 31, 2014

Feb. 08, 2013

Jun. 27, 2014

Jun. 28, 2013

Apr. 30, 2014

Feb. 10, 2014

Jan. 31, 2014

Jun. 27, 2014

Jun. 28, 2013

Dec. 31, 2006

Common Class A [Member]

Common Class A [Member]

Common Class A [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Partners For Growth [Member]

Partners For Growth [Member]

Partners for Growth One [Member]

Partners for Growth Two [Member]

Fees Waived [Member]

Fees Waived [Member]

Loans Payable [Member]

Loans Payable [Member]

Export Import Sublimit [Member]

Line of Credit [Member]

Line of Credit [Member]

Line of Credit [Member]

Bank Term Loan [Member]

Bank Term Loan [Member]

Bank Term Loan [Member]

Capital Lease Obligations [Member]

Capital Lease Obligations [Member]

Capital Lease Obligations [Member]

Silicon Valley Loan Agreement [Member]

Silicon Valley Loan Agreement [Member]

Silicon Valley Loan Agreement [Member]

Silicon Valley Loan Agreement [Member]

Silicon Valley Loan Agreement [Member]

Silicon Valley Loan Agreement [Member]

Silicon Valley Loan Agreement [Member]

SVB and PFG Agreements [Member]

SVB and PFG Agreements [Member]

SVB and PFG Agreements [Member]

SVB and PFG Agreements [Member]

SVB and PFG Agreements [Member]

SVB and PFG Agreements [Member]

SVB and PFG Agreements [Member]

SVB and PFG Agreements [Member]

SVB and PFG Agreements [Member]

SVB and PFG Agreements [Member]

SVB and PFG Agreements [Member]

SVB and PFG Agreements [Member]

SVB and PFG Agreements [Member]

Partners For Growth [Member]

Partners For Growth [Member]

Partners For Growth [Member]

Partners For Growth [Member]

Partners For Growth [Member]

Partners For Growth [Member]

Partners For Growth [Member]

Partners For Growth [Member]

Michigan Economic Development Corporation Loan Agreement [Member]

Michigan Economic Development Corporation Loan Agreement [Member]

Michigan Economic Development Corporation Loan Agreement [Member]

Partners For Growth [Member]

Partners For Growth [Member]

Partners for Growth One [Member]

Partners for Growth One [Member]

Partners for Growth Two [Member]

Partners for Growth Two [Member]

Maximum [Member]

Silicon Valley Loan Agreement [Member]

Partners For Growth [Member]

Silicon Valley Loan Agreement [Member]

Silicon Valley Loan Agreement [Member]

Silicon Valley Loan Agreement [Member]

Silicon Valley Loan Agreement [Member]

Silicon Valley Loan Agreement [Member]

Silicon Valley Loan Agreement [Member]

Silicon Valley Loan Agreement [Member]

Silicon Valley Loan Agreement [Member]

Silicon Valley Loan Agreement [Member]

Line of Credit [Member]

Period One [Member]

Period Two [Member]

Period One [Member]

Period One [Member]

Period One [Member]

Period Two [Member]

Period Two [Member]

Period Two [Member]

Period Three [Member]

Period Three [Member]

Period Three [Member]

Period Four [Member]

Period Four [Member]

Period Four [Member]

Minimum [Member]

Period One [Member]

Period Two [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Note 5 - Debt (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loans Payable to Bank

$250,000

'

$306,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Covenant Requirements Liquidity Ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.25

'

'

1.3

1.3

1.3

2

2.25

2

'

'

'

'

'

'

2

'

'

'

'

'

'

'

2.25

'

'

'

Debt Instrument Covenant Annual Earnings Before Interest Taxes Depreciation and Amortization

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-300,000

1

'

'

'

'

-850,000

-1,200,000

-800,000

-300,000

-800,000

-600,000

1

-600,000

-250,000

100,000

1

1

'

-300,000

1

'

'

'

'

'

'

'

'

'

Debt Instrument, Fee Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

'

'

'

'

Debt Instrument, Covenant Requirement, Liquidity Ratio, Compliance Fees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000

'

'

'

'

'

Proceeds from Issuance of Common Stock

2,914,000

'

'

2,657,000

398,606

2,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

'

'

'

5,391,304

'

6,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Conversion of Units (in Shares)

'

'

'

'

808,696

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument Interest Additional Interest Above Prime Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.50%

4.00%

'

0.75%

4.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Effective Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Interest Rate at Period End

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term Line of Credit

1,294,000

'

2,147,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Remaining Borrowing Capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Paid

97,000

92,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000

0

1,700

'

'

'

38,000

12,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

71,000

'

'

'

8,000

9,000

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

'

'

'

'

2,200,000

Debt Instrument, Periodic Payment, Principal

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

59,524

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11.75%

'

'

'

'

'

5.00%

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

'

'

'

'

'

1,195,000

1,195,000

995,000

995,000

200,000

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

'

'

'

'

'

'

'

'

$0.50

$0.50

$1

$1

'

'

$0.50

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum Trading Days For Calculating Closing Price of Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'45 days

'

'

'

'

'

'

'

'

Exercise Of Stock Warrants Value

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and Rights Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

434,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

179,000

'

'

'

'

'

'

'

Unsecured Debt

$654,000

'

$654,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$327,000

'

'

Note_5_Debt_Details_Total_Outs

Note 5 - Debt (Details) - Total Outstanding Debt (USD $)	Jun. 27, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified
Total Outstanding Debt [Abstract]	'	'
Bank term loan	$250	$306
Bank line of credit	1,294	2,147
MEDC/MSF loans	654	654
Partners for Growth loan, net of debt discount	1,367	1,508
Capital leases	50	56
Total	$3,615	$4,671

Note_6_Stockholders_Equity_Det

Note 6 - Stockholders' Equity (Details) (USD $)

3 Months Ended

15 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

Jun. 27, 2014

Jun. 28, 2013

Jun. 28, 2014

Mar. 31, 2014

Jun. 27, 2014

Mar. 31, 2014

Jun. 27, 2014

Mar. 31, 2014

Jun. 06, 2014

Jun. 10, 2014

Jun. 12, 2014

Nov. 29, 2010

Feb. 28, 2013

Feb. 08, 2013

Feb. 28, 2013

Feb. 08, 2013

Feb. 28, 2013

Feb. 08, 2013

Nov. 29, 2010

Jun. 06, 2014

Nov. 29, 2010

Jun. 27, 2014

Jun. 27, 2014

31-May-10

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Common Class A [Member]

Common Class A [Member]

Common Class A [Member]

Common Class A [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

2010 Warrants [Member]

2010 Warrants [Member]

2010 Warrants [Member]

Partners for Growth One [Member]

Partners for Growth Two [Member]

Michigan Economic Development Corporation Loan Agreement [Member]

Partners For Growth [Member]

Partners For Growth [Member]

Partners For Growth [Member]

Partners For Growth [Member]

Partners for Growth One [Member]

Partners for Growth One [Member]

Partners for Growth Two [Member]

Partners for Growth Two [Member]

Minimum [Member]

Note 6 - Stockholders' Equity (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

5,391,304

'

6,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

$0.53

'

'

'

'

'

'

'

'

'

'

'

'

Share Price, Discount Rate on Market Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

$0.49

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Capital Shares Reserved for Future Issuance

'

'

'

'

'

'

'

'

808,696

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Common Stock (in Dollars)

$2,914,000

'

'

'

'

'

'

'

$2,657,000

$398,606

$2,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

'

'

'

'

'

'

'

1,195,000

1,195,000

995,000

995,000

200,000

200,000

267,196

'

'

'

'

'

Exercise Period Of Warrants

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'5 years

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

Share Price Trigger (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.40

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.50

$0.50

$1

$1

'

$1.24

$1.17

$0.50

$1

'

Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net (in Dollars)

45,000

-196,000

196,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Liability, Noncurrent (in Dollars)

364,000

'

'

409,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Dividend Rate

'

'

'

'

0.00%

0.00%

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Amount (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$562,336

Debt Conversion, Converted Instrument, Shares Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,041,363

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.54

Note_6_Stockholders_Equity_Det1

Note 6 - Stockholders' Equity (Details) - Warrants Outstanding and Exercisable (USD $)	Jun. 27, 2014
In Thousands, except Per Share data, unless otherwise specified
Class of Warrant or Right [Line Items]	'
Warrants Outstanding and Exercisable	1,462
Twenty Ten Warrant [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants Outstanding and Exercisable	267
Exercise Price (in Dollars per share)	1.242
Partners for Growth One [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants Outstanding and Exercisable	995
Exercise Price (in Dollars per share)	0.5
Partners for Growth Two [Member]	'
Class of Warrant or Right [Line Items]	'
Warrants Outstanding and Exercisable	200
Exercise Price (in Dollars per share)	1

Note_6_Stockholders_Equity_Det2

Note 6 - Stockholders' Equity (Details) - Assumptions Used to Estimate Fair Value of Warrants (Warrant [Member])	3 Months Ended	12 Months Ended
	Jun. 27, 2014	Mar. 31, 2014
Fair Value, Option, Quantitative Disclosures [Line Items]	'	'
Contractual term in years	'1 year 146 days	'1 year 255 days
Volatility	73.30%	69.50%
Expected dividend	0.00%	0.00%
Risk-free interest rate	0.25%	0.34%
Partners For Growth [Member]	'	'
Fair Value, Option, Quantitative Disclosures [Line Items]	'	'
Contractual term in years	'3 years 219 days	'3 years 328 days
Volatility	68.90%	65.60%
Expected dividend	0.00%	0.00%
Risk-free interest rate	1.12%	1.25%

Note_6_Stockholders_Equity_Det3

Note 6 - Stockholders' Equity (Details) - Activity in Level Three Warrants (USD $)	3 Months Ended	12 Months Ended
	Jun. 27, 2014	Mar. 31, 2014
Activity in Level Three Warrants [Abstract]	'	'
Level 3 Warrants, beginning of period	$409,000	$292,000
Change in fair value of warrant liability	-45,000	117,000
Level 3 Warrants, end of period	$364,000	$409,000

Note_7_Earnings_Per_Share_Deta

Note 7 - Earnings Per Share (Details) - Calculation of Income Loss Per Share (USD $)	3 Months Ended
	Jun. 27, 2014	Jun. 28, 2013
Calculation of Income Loss Per Share [Abstract]	'	'
Weighted Average Basic Shares Outstanding	32,642,000	31,198,000
Dilutive effect of Stock Options and Warrants	'	'
Weighted Average Diluted Shares Outstanding	32,642,000	31,198,000
Net loss (in Dollars)	($268,000)	($925,000)
Basic loss per share (in Dollars per share)	($0.01)	($0.03)
Diluted loss per share (in Dollars per share)	($0.01)	($0.03)